Mortality outcomes associated with oral corticosteroid use in patients with COPD
G. Tse (Singapore, Singapore), D. Price (Singapore, Singapore), M. Bafadhel (Oxford, United Kingdom), A. Papi (Ferrara, Italy), V. Carter (Singapore, Singapore), C. Ariti (Singapore, Singapore), J. Zhou (Singapore, Singapore), D. Skinner (Singapore, Singapore), X. Xu (Gaithersburg, MD, United States), H. Müllerová (Cambridge, United Kingdom), B. Emmanuel (Gaithersburg, MD, United States)
Source: International Congress 2022 – COPD clinical studies and exacerbations
Session: COPD clinical studies and exacerbations
Session type: Thematic Poster
Number: 3607
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Tse (Singapore, Singapore), D. Price (Singapore, Singapore), M. Bafadhel (Oxford, United Kingdom), A. Papi (Ferrara, Italy), V. Carter (Singapore, Singapore), C. Ariti (Singapore, Singapore), J. Zhou (Singapore, Singapore), D. Skinner (Singapore, Singapore), X. Xu (Gaithersburg, MD, United States), H. Müllerová (Cambridge, United Kingdom), B. Emmanuel (Gaithersburg, MD, United States). Mortality outcomes associated with oral corticosteroid use in patients with COPD. 3607
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|